• Evaluation of the Intraduodenal Lipase activity following administration of pancrelipase MT20 capsules with a high-fat liquid meal [ Time Frame: Evaluation of the Intraduodenal Lipase activity following administration of pancrelipase MT20 capsules with a high-fat liquid meal ] [ Designated as safety issue: No ]
  

• Evaluation of the Intraduodenal Amylase and Protease activities following administration of pancrelipase MT20 capsules with a high-fat liquid meal [ Time Frame: Evaluation of the Intraduodenal Amylase and Protease activities following administration of pancrelipase MT20 capsules with a high-fat liquid meal ] [ Designated as safety issue: No ]
  

This is a single-dose, open-label, randomized, 2-way crossover study of pancrelipase MT. The study consists of a screening phase and an open label treatment phase (2 treatment phases). In the screening phase, patients will undergo screening procedures prior to entry into the study and will be instructed to stop taking their existing pancreatic enzyme supplement, if applicable, for 72 hours before admission into the study center for the open-label phase. In the open-label phase, the patient will participate in both treatment phases in random order. In each treatment phase, patients will be intubated with a Dreiling-like tube and receive a treatment (a high-fat liquid meal or 3 pancrelipase MT20 capsules administered with a high-fat liquid meal). Duodenal and gastric samples will be collected with the tube. There is 1-day resting period between the 2 treatment phases. Safety and tolerability will be assessed by adverse events; laboratory tests, including hematology, serum chemistry, and urinalysis; vital sign measurements, including oral temperature, heart and respiratory rates, and blood pressure.

3 pancrelipase MT20 capsules (total of 60,000 U.S.P. units of lipase), oral administration simultaneously with a high-fat liquid meal